Why the study?
Does TAVR using current-generation devices provide comparable outcomes in patients with bicuspid aortic valve disease compared to those with tricuspid aortic valve disease?
Does TAVR using current-generation devices provide comparable outcomes in patients with bicuspid aortic valve disease compared to those with tricuspid aortic valve disease?
TAVR with newer-generation devices is a viable treatment option for patients with bicuspid aortic valve disease, demonstrating comparable 1-year outcomes to those with tricuspid anatomy.
Comparable TAVR outcomes in bicuspid AV support feasibility; hypothesis-generating and leaves open randomized confirmation.
Using current-generation devices, procedural, postprocedural, and 1-year outcomes were comparable following TAVR for bicuspid AV versus tricuspid AV disease. With newer-generation devices, TAVR is a viable treatment option for patients with bicuspid AV disease.
No takes yet. Share an insight, caveat, or question.
Halim et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: